ArticleClinical science (London, England : 1979)2023
Circulating biomarkers associated with placental dysfunction and their utility for predicting fetal growth restriction.
Article in Clinical science (London, England : 1979), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Maternal opioid use and hepatitis C infection disrupt the placental immune landscape and structure.JCI insight · 2026Article
- The KISS1/KISS1R Axis in Human Placentation: Molecular Mechanisms and Implications for Foetal Growth Restriction and Pre-Eclampsia.International journal of molecular sciences · 2026Review
- Cumulative High-Risk Pregnancy Complications and Stunting Risk in Indonesian Children Younger Than 5 Years: Retrospective Analysis Using the Developmental Origins of Health and Disease Framework.Asian/Pacific Island nursing journal · 2026Article
- Association of maternal IL-2, IL-4, and IL-13 with intrauterine growth restriction and umbilical artery doppler: a case-control study.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2026Article
- Research priorities for stillbirth in Australia: outcomes of a national priority setting partnership.BMC pregnancy and childbirth · 2025Article
- Emerging biomarkers for gestational diabetes mellitus and related pediatric outcomes.World journal of clinical pediatrics · 2025Review
- Obstetric complications in pregnant people with Fontan circulation: Identifying candidate pathologic pathways in the placenta.Pregnancy (Hoboken, N.J.) · 2025Article
- Maternal opioid use with and without hepatitis C infection disrupts the structure and immune landscape of the maternal-fetal interface.bioRxiv : the preprint server for biology · 2025Article
- Notch signaling pathway regulates the progression of fetal growth restriction through mediating immune dysfunction.Biomedical reports · 2025Article
- Application of Proteomics in Maternal and Neonatal Health: Advancements and Future Directions.Proteomics. Clinical applications · 2025Review
- Enhancing birth weight outcomes through improved antenatal care in West African countries: Evidence from propensity score matching analysis.PLOS global public health · 2025Article
- The Relationship between Placental Shear Wave Elastography and Fetal Weight-A Prospective Study.Journal of clinical medicine · 2024Article
- Prediction of preterm birth in women with fetal growth restriction - Is the weekly change in sFlt-1/PlGF ratio or PlGF levels useful?Acta obstetricia et gynecologica Scandinavica · 2024Article
- The influence of birthweight on mortality and severe neonatal morbidity in late preterm and term infants: an Australian cohort study.The Lancet regional health. Western Pacific · 2024Article
- Quantitative Proteomics of Maternal Blood Plasma in Isolated Intrauterine Growth Restriction.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fetal growth restriction (FGR) leading to low birth weight (LBW) is a major cause of neonatal morbidity and mortality worldwide. Normal placental development involves a series of highly regulated processes involving a multitude of hormones, transcription factors, and cell lineages. Failure to achieve this leads to placental dysfunction and related placental diseases such as pre-clampsia and FGR. Early recognition of at-risk pregnancies is important because careful maternal and fetal surveillance can potentially prevent adverse maternal and perinatal outcomes by judicious pregnancy surveillance and careful timing of birth. Given the association between a variety of circulating maternal biomarkers, adverse pregnancy, and perinatal outcomes, screening tests based on these biomarkers, incorporating maternal characteristics, fetal biophysical or circulatory variables have been developed. However, their clinical utility has yet to be proven. Of the current biomarkers, placental growth factor and soluble fms-like tyrosine kinase 1 appear to have the most promise for placental dysfunction and predictive utility for FGR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.